Very interesting article in today’s issue of Mass High Tech. Is this finally the end of the “heartbreak of presbyopia?”
Dick
www.aerovisiontech.com
Cambridge eyecare entrepreneur scouts familiar territory south of the border
06/20/2005 08:07 AM
By Dyke Hendrickson
Not many startups look to Mexico City for initial funding but Osio Corp. has launched with a unique game plan.
Its principals are from Mexico, and soon they will be calling on deep-pocketed investors there with hopes of getting the nascent company off the ground. “Mexico doesn’t have venture money exactly,” said Alberto Osio, a founder of the Cambridge vision-enhancement company, “but there are people there with money, and they would be acting as angels.
“We need to raise money so that we can move toward approval from the Food and Drug Administration. And we don’t think it’s that far off.”
Osio schooled in Mexico and is a MBA student at MIT’s SloanSchool. Osio Corp. was a finalist in the recent Harvard Biotechnology Club business plan competition. His experience includes six years of international management experience with Hormel Foods and Grupo Herdez (Mexico’s largest food company) in Mexico, United States and China.
Another asset he possesses is a close link to an eminent scientist — his father. Chief scientific officer is Dr. Alberto Osio Sancho, a surgeon in Mexico City. Osio Sancho is an experienced practitioner in the field of refractive and cataract surgery and the inventor of the company’s technology. Company officials say he is recognized internationally as a pioneer in refractive surgery.
Which is good, because Osio Corp. is focusing on eye care.
It is targeting presbyopia, a common condition that degrades the eye’s ability to focus on close objects. It is prevalent among those nearing middle-age whose diminishing sight requires them to consider glasses, especially for reading. Osio’s patent-pending Topical Presbyopia Procedure purports to be a safe, non-invasive and effective procedure available to treat presbyopes using a combination of personalized contact lenses, specially formulated eye drops and specification software. Under Dr. Osio’s direction, close to 150 individuals in controlled trials using the TOPP technology have been treated successfully.
The next stage of development will be to raise money and start trials. To that end, the company is looking to add members to its management team.
Company officials say its competitive advantage lies in the capability to correct presbyopia without invasive surgery or recurring eyeglasses or contact lens costs. Osio has patented its TOPP treatment method. And the new company is targeting a large economic opportunity.
Almost 70 million Baby Boomers require some optical aids, according to national figures. Osio officials say these people are under-served because they are not “perfect candidates” for surgery, and might not want to continue to wear contacts or reading glasses.
Jonathan Fleming, managing partner at Oxford Bioscience Partners, said he is impressed with the fledgling enterprise. “I like the spirit and ambition of the company,” said Fleming, who met Alberto Osio while he (Fleming) was teaching an entrepreneurship course at MIT. “Its members have showed initiative, and they’ve got good people involved, including Alberto’s father, who showed that this technology works.
“They are focusing on a condition that is a problem for many people. One of their challenges after developing the product is to find customers who will choose that option and pay the price point that Osio eventually sets.
“It’s a crowded marketplace but there is a need.”
Osio offers a solution in which TOPP reshapes the cornea to change the focal distance of light entering the eye using personalized contact lenses as a corneal shape pattern and specially formulated eye drops as a catalytic agent. The TOPP course of treatment can be prescribed by an optometrist. It is completed within two weeks, depending on the patient and level of correction required.
Robert Langer, the award-winning MIT professor and inventor, said their technology has potential. “I know them a little,” he said, “and they seem smart, nice.” adding that the company is pursuing a large economic target.
Citation: http://www.masshightech.com/displaya...p?art_ID=68948
Bookmarks